Measuring Lung Mechanics in Patients With COPD Using the REOM Handheld Portable Device
- Conditions
- Copd
- Interventions
- Device: Rapid Expiratory Occlusion Monitor (REOM)Diagnostic Test: Standard oscillometryDiagnostic Test: Standard pulmonary function test
- Registration Number
- NCT05913323
- Lead Sponsor
- McGill University Health Centre/Research Institute of the McGill University Health Centre
- Brief Summary
The purpose the study is to determine the agreement between the information obtained about lung mechanics (lung function) from the Rapid Expiratory Occlusion Monitor (REOM) handheld portable device with that obtained by conventional oscillometry as well as by pulmonary function testing (PFT), in patients with both 'mild' as well as 'very severe' forms of chronic obstructive pulmonary disease (COPD). This study also intends to study the user experience with this handheld portable device.
- Detailed Description
The primary objective of this cross-sectional study is to determine the concordance and agreement between the parameters obtained from the REOM, Reo1 and Reo2, and the conventional resistance parameters obtained by the tremoflo oscillometer device (R19 and R5, respectively) in adults with COPD confirmed by diagnostic pulmonary function testing (PFT).
The secondary objectives are:
1. To investigate the discriminative capacity of the parameters obtained from the REOM to distinguish between 'mild' and 'very severe' COPD.
2. To collect descriptive information on the participant user experience with the REOM.
3. To determine concordance between the parameters obtained from the REOM and those obtained from the tremoflo oscillometry device with the 'standard' parameters obtained from each participant's standard Pulmonary Function Tests (PFT).
Hypothesis:
We hypothesize in the adult COPD patient population that the REOM parameter Reo1 and tremoflo device parameter R19 will correlate closely, and that the REOM parameter Reo2 and tremoflo device parameter R5 will correlate closely. We also hypothesize that the REOM, in particular, Reo2, will be able to distinguish between 'mild' and 'very severe' COPD, and that participants will report a positive user experience with the REOM.
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- All
- Target Recruitment
- 19
- Males and females aged ≥40 with COPD, former/current smokers with a ≥10 pack-year smoking history.
- Diagnosed with COPD by FEV1/FVC < 0.7 using standard PFT post-bronchodilator testing, with either 'mild' ('GOLD 1': FEV1 ≥ 80% of predicted value) COPD or 'very severe' ('GOLD 4': FEV1 < 30% of predicted value) COPD.
- Ability to provide informed consent.
- No existing COPD diagnosis
- History of co-morbid asthma
- Current use of home oxygen
- Any acute exacerbation of COPD (AECOPD) experienced within 4 weeks of participation in the study
- Chronic respiratory infection
- Any contraindication to respiratory testing
- Inability to participate in reproducible measurements due to physical or cognitive barrier
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description COPD sub-group: GOLD 1 COPD Standard pulmonary function test A secondary objective of the study is to investigate the discriminative capacity of the parameters obtained from the REOM to distinguish between 'mild' and 'very severe' COPD. Thus, there will be a 'mild' (GOLD 1) COPD sub-group. COPD sub-group: GOLD 1 COPD Rapid Expiratory Occlusion Monitor (REOM) A secondary objective of the study is to investigate the discriminative capacity of the parameters obtained from the REOM to distinguish between 'mild' and 'very severe' COPD. Thus, there will be a 'mild' (GOLD 1) COPD sub-group. COPD sub-group: GOLD 4 COPD Rapid Expiratory Occlusion Monitor (REOM) A secondary objective of the study is to investigate the discriminative capacity of the parameters obtained from the REOM to distinguish between 'mild' and 'very severe' COPD. Thus, there will be a 'very severe' (GOLD 4) COPD sub-group. COPD sub-group: GOLD 4 COPD Standard pulmonary function test A secondary objective of the study is to investigate the discriminative capacity of the parameters obtained from the REOM to distinguish between 'mild' and 'very severe' COPD. Thus, there will be a 'very severe' (GOLD 4) COPD sub-group. COPD sub-group: GOLD 1 COPD Standard oscillometry A secondary objective of the study is to investigate the discriminative capacity of the parameters obtained from the REOM to distinguish between 'mild' and 'very severe' COPD. Thus, there will be a 'mild' (GOLD 1) COPD sub-group. COPD sub-group: GOLD 4 COPD Standard oscillometry A secondary objective of the study is to investigate the discriminative capacity of the parameters obtained from the REOM to distinguish between 'mild' and 'very severe' COPD. Thus, there will be a 'very severe' (GOLD 4) COPD sub-group.
- Primary Outcome Measures
Name Time Method Concordance (correlation) Single-visit study: all tests performed at one single visit. Correlation will be tested using the Spearman correlation coefficient (r) between REOM-obtained (Reo1 and Reo2) and tremoflo-obtained (R19 and R5) resistance measurements.
Agreement Single-visit study: all tests performed at one single visit. Agreement will be tested using the Bland-Altman test between REOM-obtained (Reo1 and Reo2) and tremoflo-obtained (R19 and R5) resistance measurements.
- Secondary Outcome Measures
Name Time Method Discriminative capacity Single-visit study: all tests performed at one single visit. The t-test (between 2 independent means) will be used to determine the discriminative capacity of the REOM to distinguish between 'mild' and 'very severe' COPD.
Participant satisfaction and usability experience Single-visit study: all tests performed at one single visit. Each participant will complete a 'participant satisfaction questionnaire' as well as the validated System Usability Scale (SUS) for each test (REOM, standard oscillometry, pulmonary function test). Data will be presented descriptively.
Trial Locations
- Locations (1)
McGill University Health Centre
🇨🇦Montréal, Quebec, Canada